Calithera Biosciences Inc. (NASDAQ:CALA) shares reached a new 52-week low during trading on Tuesday . The company traded as low as $3.60 and last traded at $3.67, with a volume of 33,103 shares trading hands. The stock had previously closed at $3.81.

A number of research analysts recently commented on CALA shares. Wells Fargo & Co. reissued a “buy” rating on shares of Calithera Biosciences in a research note on Thursday, May 12th. Zacks Investment Research raised Calithera Biosciences from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research note on Tuesday, March 22nd. JMP Securities reissued a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Finally, JPMorgan Chase & Co. reduced their target price on Calithera Biosciences from $20.00 to $12.00 and set a “market outperform” rating on the stock in a research note on Wednesday, March 9th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Calithera Biosciences presently has a consensus rating of “Buy” and a consensus target price of $10.48.

The stock’s market capitalization is $72.22 million. The firm has a 50 day moving average price of $4.60 and a 200-day moving average price of $5.46.

Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Tuesday, May 10th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by $0.05. Equities research analysts predict that Calithera Biosciences Inc. will post ($2.15) EPS for the current year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.